Skip to main content
SpringerLink
Log in

Cannabis medicines cost effective for MS spasticity?

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. CINAHL, EconLit, Embase, Medline, PreMedline, PsycINFO, the NHS Economic Evaluation Database, and Tufts' Cost-Effectiveness Analysis Registry

Reference

  • Herzog S, et al. Systematic Review of the Costs and Benefits of Prescribed Cannabis-Based Medicines for the Management of Chronic Illness: Lessons from Multiple Sclerosis. PharmacoEconomics : 2 Sep 2017. Available from: URL: http://dx.doi.org/10.1007/s40273-017-0565-6

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cannabis medicines cost effective for MS spasticity?. PharmacoEcon Outcomes News 786, 8 (2017). https://doi.org/10.1007/s40274-017-4298-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-4298-8

Search

Navigation